Sweden approves generic copy of GSK's top lung drug

LONDON Tue Jan 14, 2014 7:37am EST

LONDON Jan 14 (Reuters) - Sweden has followed Denmark and Germany in approving the sale of a generic copy of GlaxoSmithKline's $8 billion-a-year inhaled lung drug Advair.

Britain's Vectura said on Tuesday its partner Sandoz, the generics division of Switzerland's Novartis , had received Swedish authorisation for its generic version of the drug, known as AirFluSal Forspiro.

The initial Danish green light was given to the product in December.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.